Pharmaceutical - Pharmaceutical, Entyvio

Filter

Current filters:

PharmaceuticalEntyvio

Popular Filters

Added benefit of Takeda’s Entyvio is not proven, says IQWiG

Added benefit of Takeda’s Entyvio is not proven, says IQWiG

04-11-2014

In an early benefit assessment pursuant to the Act on the Reform of the Market for Medicinal Products,…

EntyvioGastro-intestinalsGermanyPharmaceuticalPricingRegulationTakeda Pharmaceutical

Takeda presents Phase III data for Entyvio in UC and Crohn’s Disease

Takeda presents Phase III data for Entyvio in UC and Crohn’s Disease

02-10-2014

Japan’s largest drugmaker Takeda Pharmaceutical today announced new data from a Phase III study of…

EntyvioGastro-intestinalsJapanPharmaceuticalResearchTakeda Pharma

Opportunity for emerging agents in Crohn’s disease, report finds

Opportunity for emerging agents in Crohn’s disease, report finds

18-09-2014

New research from Decision Resources Group has found that only a small proportion of patients with Crohn's…

Anti-Arthritics/RheumaticsBiosimilarsEntyvioHumiraPharmaceuticalRemicadeResearchStelaraUSAXeljanz

Takeda launches first gut-selective treatment for inflammatory bowel disease in the UK

Takeda launches first gut-selective treatment for inflammatory bowel disease in the UK

28-08-2014

The first gut-selective treatment for ulcerative colitis and Crohn’s Disease is now available in the…

Crohn's diseaseEntyvioGastro-intestinalsInflammatory bowel diseasePharmaceuticalRegulationTakeda PharmaceuticalUKUlcerative colitis

Approval of Takeda’s Entyvio marks “historic change” for IBD treatment

Approval of Takeda’s Entyvio marks “historic change” for IBD treatment

03-06-2014

The recent approval of Japanese drug major Takeda’s Entyvio (vedolizumab) by the European Medicines…

EntyvioGastro-intestinalsHumiraMarkets & MarketingPharmaceuticalRemicadeSimponi InjectionStelaraTakeda Pharmaceutical

EU approval for Takeda’s Entyvio for UC and Crohn’s disease

27-05-2014

Takeda Pharmaceutical, Japan’s largest drugmaker has received marketing approval from the European…

EntyvioEuropeGastro-intestinalsPharmaceuticalRegulationTakeda Pharmaceutical

US FDA thumbs up for Takeda’s Entyvio for ulcerative colitis and Crohn's disease

US FDA thumbs up for Takeda’s Entyvio for ulcerative colitis and Crohn's disease

21-05-2014

The US Food and Drug Administration yesterday approved Entyvio (vedolizumab) injection, from Japan’s…

EntyvioGastro-intestinalsPharmaceuticalRegulationTakeda PharmaceuticalsUSA

Takeda gets positive CHMP opinion for Entyvio for UC and Crohn’s disease

21-03-2014

Takeda Pharmaceutical, Japan’s largest drugmaker, today received a positive opinion form the European…

EntyvioEuropeGastro-intestinalsPharmaceuticalRegulationTakeda Pharmaceuticals

Global ulcerative colitis market to reach $6.6 billion by 2022

Global ulcerative colitis market to reach $6.6 billion by 2022

14-02-2014

The global ulcerative colitis market value will increase steadily over the coming years, increasing from…

AbbVieEntyvioGastro-intestinalsGlobalHumiraJohnson & JohnsonMarkets & MarketingPharmaceuticalRemicadeSimponi InjectionTakeda Pharmaceuticals

Modest growth forecast for global Crohn’s disease market

Modest growth forecast for global Crohn’s disease market

04-02-2014

The global Crohn’s disease (CD) market value is forecast to show modest growth, climbing from $3.2…

AbbVieBiotechnologyEntyvioGastro-intestinalsGlobalHumiraJohnson & JohnsonMarkets & MarketingPharmaceuticalRemicadeStelara InjectionTakeda Pharmaceuticals

Back to top